Yale-New Haven Hospital-Yale Cancer Center

New Haven, Connecticut 06520

11 studies enrolling now · 20 studies all time

What they study most

1st Line NSCLC, Adenocarcinoma of Lung, Advanced Breast Cancer, Advanced Non-Small Cell Lung Cancer, Advanced Solid Tumor, Advanced/Metastatic Solid Tumors, Bladder Cancer, Breast Cancer, Breast Neoplasms, CRC, Cancer, Malignant Tumors, Carcinoma, Non Small Cell Lung

Studies at this site

• Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer — Recruiting now
• A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) — Recruiting now
• Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors — Recruiting now
• A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors — Recruiting now
• Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers — Recruiting now
• A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence — Recruiting now
• Study of HLD-0915 in Patients With Metastatic Prostate Cancer — Recruiting now
• A Study of HLD-0117 in Patients With Metastatic Breast Cancer — Recruiting now
• Study of PF-07248144 in Advanced or Metastatic Solid Tumors — Recruiting now
• A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies — Recruiting now
• FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors — Recruiting now
• Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors — Running, not enrolling
• A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 — Running, not enrolling
• Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. — Stopped early
• Mirdametinib + BGB-3245 in Advanced Solid Tumors — Stopped early
• A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies — Stopped early
• A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer. — Running, not enrolling
• Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy — Running, not enrolling
• Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors — Running, not enrolling
• A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas — Completed